Dr. Nalamothu will present a session titled, Preclinical Activities on the Critical Path, which will focus on the considerations and strategies needed to successfully bring a topical dermatological product to market. Dr. Nalamothu, whose deep expertise in topical pharmaceuticals makes him uniquely qualified to lead the session, will educate entrepreneurs on how to bring a topical pharmaceutical to market. Some of the specific subjects that will be covered include: preclinical aspects leading to entry into humans, including CMC and formulation/delivery strategies for pharmacology, toxicology, etc.
Under Dr. Nalamothu’s leadership, Tergus has enjoyed strong growth for the past few years. It continues to grow its footprint, recently expanding to a more than 28,000 square-foot facility that includes top-of-the-line R&D labs, GMP manufacturing suite and the largest capability in the industry for IVRT and skin permeation studies. Tergus pioneered QbD for topical pharmaceuticals and continues to innovate and develop strategies that result in greater success for its clients.
Tergus CEO, Vijendra Nalamothu, will be co-leading the Entrepreneur Boot Camp at the 2nd annual Dermatology Entrepreneur Conference, March 3, 2016. Tergus is also a sponsor of the event and will have a booth in the exhibition hall in the Ronald Reagan Building International Trade Center, Washington, D. C.
The 2nd Annual Dermatology Entrepreneurship conference will focus on fostering the early development of innovative products and services by physicians and entrepreneurs for dermatologic health. Held the day prior to the start of the annual American Academy of Dermatology meeting, the conference will serve to inspire and educate physicians and entrepreneurs in the skills and steps necessary to bring forward their ideas and inventions. It will simultaneously function as a networking event for cultivating an entrepreneurial ecosystem that includes physicians, researchers, entrepreneurs, investors, strategic corporate partners, service providers and other stakeholders.